CTIS2024-513106-62-00进行中（未招募）1 期
LAMOT-04-24
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA)age= 75 yearshypertensionsymptomatic heart failure (NYHA Class = II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.MedDRA version: 21.1Level: PTClassification code: 10051055Term: Deep vein thrombosis Class: 100000004866MedDRA version: 23.1Level: LLTClassification code: 10084868Term: Systemic embolism Class: 100000004848MedDRA version: 20.0Level: LLTClassification code: 10014521Term: Embolism pulmonary Class: 10038738diabetes mellitusCTIS2024-511526-31-00Celon Pharma S.A.38
进行中（未招募）
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872CTIS2023-503968-16-00Bayer Consumer Care AG16
招募中
1 期
A study to learn if UCB3101 is safe and how it moves through the body of healthy participantsHealthy ParticipantsMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848CTIS2023-504586-24-00CB Biopharma88
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritisMedDRA version: 21.0Level: LLTClassification code: 10037160Term: Psoriatic arthritis Class: 10028395MedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856MedDRA version: 23.1Level: LLTClassification code: 10003268Term: Arthritis rheumatoid Class: 10028395MedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856MedDRA version: 21.1Level: PTClassification code: 10071400Term: Axial spondyloarthritis Class: 100000004859CTIS2024-512770-10-00Sun Pharmaceutical Industries Limited50
进行中（未招募）
1 期
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumorsOvarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2024-511238-11-00Eli Lilly & Co.216